CRIS Current Research Information System

ROSELLINI, MATTEO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.162
NA - Nord America 1.358
EU - Europa 900
SA - Sud America 197
AF - Africa 132
Totale 5.749
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.308
SG - Singapore 949
CN - Cina 803
VN - Vietnam 698
HK - Hong Kong 275
IT - Italia 269
KR - Corea 169
BR - Brasile 142
NL - Olanda 140
DE - Germania 88
IN - India 85
SE - Svezia 70
FR - Francia 61
GB - Regno Unito 50
CI - Costa d'Avorio 48
FI - Finlandia 46
JP - Giappone 42
SC - Seychelles 35
IE - Irlanda 34
CA - Canada 33
ZA - Sudafrica 32
RU - Federazione Russa 29
CH - Svizzera 25
PH - Filippine 24
AR - Argentina 20
AT - Austria 20
TH - Thailandia 20
JO - Giordania 17
ID - Indonesia 16
BG - Bulgaria 15
PL - Polonia 13
CL - Cile 12
BD - Bangladesh 11
ES - Italia 8
CO - Colombia 7
IQ - Iraq 7
LT - Lituania 7
TW - Taiwan 7
BE - Belgio 6
EC - Ecuador 6
MX - Messico 6
PK - Pakistan 6
JM - Giamaica 5
TR - Turchia 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
DZ - Algeria 3
KG - Kirghizistan 3
KZ - Kazakistan 3
PT - Portogallo 3
SA - Arabia Saudita 3
TG - Togo 3
UA - Ucraina 3
UY - Uruguay 3
VE - Venezuela 3
AZ - Azerbaigian 2
DO - Repubblica Dominicana 2
HR - Croazia 2
IL - Israele 2
KE - Kenya 2
ML - Mali 2
MY - Malesia 2
NI - Nicaragua 2
OM - Oman 2
PE - Perù 2
PY - Paraguay 2
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BY - Bielorussia 1
CD - Congo 1
CR - Costa Rica 1
CY - Cipro 1
EE - Estonia 1
EG - Egitto 1
GR - Grecia 1
HN - Honduras 1
IR - Iran 1
KW - Kuwait 1
LB - Libano 1
LV - Lettonia 1
MA - Marocco 1
MK - Macedonia 1
MU - Mauritius 1
MZ - Mozambico 1
RO - Romania 1
RS - Serbia 1
SN - Senegal 1
TN - Tunisia 1
Totale 5.749
Salva come PNG Salva come JPEG
Città #
Singapore 676
Hefei 295
Hong Kong 253
Ashburn 214
Hanoi 186
Ho Chi Minh City 179
San Jose 173
Seoul 165
Santa Clara 105
Beijing 84
Bologna 64
Boardman 54
Los Angeles 53
Council Bluffs 50
Abidjan 48
New York 46
Chandler 40
Dublin 33
Tokyo 32
Da Nang 31
Dallas 30
Lauterbourg 29
Helsinki 28
Johannesburg 28
Bengaluru 27
Milan 26
Guangzhou 25
Haiphong 23
Bern 22
Redondo Beach 22
Amsterdam 21
Shanghai 18
Amman 17
Castel Maggiore 17
Nuremberg 17
Frankfurt am Main 16
Biên Hòa 15
Buffalo 15
Hyderabad 15
Lappeenranta 15
Rome 14
São Paulo 14
Montreal 13
Munich 13
Orem 13
Sofia 13
Vienna 13
Falkenstein 11
London 11
Tongling 11
Turin 11
Fairfield 10
Ninh Bình 10
Princeton 10
Chicago 9
Hải Dương 9
Southend 9
Warsaw 9
Atlanta 8
Nanjing 8
Boston 7
Florence 7
Jakarta 7
Phoenix 7
Quận Bình Thạnh 7
Rimini 7
Shenzhen 7
Thái Nguyên 7
Zhengzhou 7
Brooklyn 6
Brussels 6
Can Tho 6
Changsha 6
Chennai 6
Houston 6
Manila 6
Moscow 6
Paris 6
Phú Thọ 6
Stockholm 6
Thái Bình 6
Bangkok 5
Bari 5
Berlin 5
Columbus 5
Enschede 5
Hoofddorp 5
Manchester 5
Quezon City 5
Quảng Ngãi 5
Quận Hai 5
Redmond 5
San Francisco 5
San Polo di Torrile 5
Toronto 5
Tân Tiến 5
Wuhan 5
Xi'an 5
Barnet 4
Belo Horizonte 4
Totale 3.654
Salva come PNG Salva come JPEG
Nome #
Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: A single-center experience 197
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis 172
Dual-energy spectral CT in renal cell carcinoma: dawn of a brand-new era? 170
Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma 167
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies 163
Bone targeting agents in patients with metastatic prostate cancer: State of the art 162
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 161
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 161
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 160
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 157
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 153
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study 152
Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives 149
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience 149
The value of molecular features in predicting efficacy of immuno-combinations in kidney cancer: just a drop in the ocean? 148
State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes 143
Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience 132
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis 129
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review 124
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis 123
Overall survival with adjuvant pembrolizumab in renal cell carcinoma — the shock of the lightning 112
The Prognostic Role of 68GA-PSMA-PET/CT in Metastatic Hormone-Sensitive Prostate Cancer: A Preliminary Analysis 111
The molecular characteristics of non‐clear cell renal cell carcinoma: What’s the story morning glory? 110
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma 101
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations 99
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 94
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy 91
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma 89
Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges 88
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations 86
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 85
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials 83
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? 82
Treating prostate cancer by antibody-drug conjugates 81
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers 80
Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials 80
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study 75
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab 74
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma? 72
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis 70
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer 70
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? 69
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer 67
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study 67
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis 66
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma 63
Current androgen receptor antagonists under investigation for resistant prostate cancer 56
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study 55
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study 53
Pathological and Clinical Implications of Tumor Microenvironment Evaluated With Multiplex Immunohistochemistry in Testicular Embryonal Carcinoma 53
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study 51
Prostate cancer and novel pharmacological treatment options - what's new for 2022? 45
Re: First-line Therapy for Advanced Non-Clear Cell Renal Cell Carcinoma. A Systematic Review and Meta-analysis 41
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 40
Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: A critical overview of recent evidence 38
Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial 38
An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma 37
Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials 36
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study 35
Advancements of investigational agents for renal cell carcinoma: what clinical progress have we seen in the last 5 years? 32
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study 30
Totale 5.877
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.228
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.228
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215 0 0 0 0 0 0 0 0 0 0 0 5
2021/202292 0 0 1 3 2 1 8 21 6 3 33 14
2022/2023365 5 15 7 17 36 35 21 19 95 11 55 49
2023/2024228 19 36 21 14 18 27 7 17 13 16 24 16
2024/20251.514 72 153 104 87 166 61 91 56 39 122 220 343
2025/20263.666 366 531 342 318 383 140 404 144 649 287 102 0
Totale 5.877